Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation.


BACKGROUND Targeted biologic therapies have made a significant impact on the treatment for moderate to severe psoriasis. In the United Kingdom, the National Institute for Health and Clinical Excellence recommends etanercept, a human recombinant tumour necrosis factor (TNF) receptor fusion protein, for moderate to severe psoriasis patients who have failed… (More)
DOI: 10.1111/j.1468-3083.2009.03325.x


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.